For example, repaglinide may enhance and/or prolong the hypoglycemic effect of repaglinide and, thereby, increase the risk of hypoglycemia when combined with clopidogrel, ketoconazole, and angiotensin-converting enzyme inhibitors (Plosker and Figgitt, 2004; Takayama et al., 2021). The gene discussed is ACE; the disease is Hypoglycemia.